Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to learn about the relative bioavailability (the
extent to which the drug becomes available to the body) and pharmacokinetics (blood levels)
of rivaroxaban in healthy participants after receiving a 20 mg rivaroxaban tablet orally as a
whole tablet, crushed and mixed in applesauce, and as a suspension through a Naso-gastric
(NG) tube. The relative bioavailability of rivaroxaban may be different when given as a
crushed tablet compared with an intact (whole) tablet and when given via an NG tube. The
safety and tolerability of rivaroxaban will also be assessed.